The World Orphan Drug Congress USA 2026 is presented by Terrapinn as a major global meeting point for the rare disease and orphan drug community, bringing together more than 2 000 participants from over 50 countries in Boston on 9–11 June 2026. Over three days, the congress combines plenary sessions, focused thematic streams and pre‑conference workshops that cover patient data, next generation therapies, clinical development and regulation, pricing and reimbursement, AI and digital health, diagnosis and drug discovery, early access programmes and real‑world evidence. The programme features .
Alongside the scientific and policy content, the event places strong emphasis on networking and partnership building through panel discussions, roundtables, exhibition space, one‑to‑one partnering meetings and a start‑up and innovation showcase. Patient advocates, hospital and healthcare professionals, European Reference Networks and investors are actively encouraged to take part, with a limited number of complimentary VIP passes and opportunities for poster presentations on the expo floor. For ERDERA, this congress offers a platform to strengthen international alignment, clinical research collaboration and data‑driven innovation with global partners working on rare diseases and orphan drugs.